2C46FD44-DE8D-4477-874C-FB561E8987EBCHARACTERISING KYNURENINE 3-MONOOXYGENASE (KMO) AS A THERAPEUTIC TARGET FOR HUNTINGTON'S DISEASEResearch GrantMR/N00373X/1C008C651-F5B0-4859-A334-5F574AB6B57CMRCINCOME_ACTUAL8046962C1D3E44-76F5-43BE-8004-A89F47CD47C3Ablation of kynurenine 3-monooxygenase rescues plasma inflammatory cytokine levels in the R6/2 mouse model of Huntington's disease.Scientific reportsb0cf358661ae9b43ce4f68a6ef7af3d0Bondulich MK2021-01-01http://dx.doi.org/10.1038/s41598-021-84858-733750843http://ukpmc.ac.uk/abstract/MED/337508432045-2322http://europepmc.org/abstract/MED/33750843111Journal Article/Review604a015ba9bc18.86794670